Pharmaxis Appoints Former Head of Global Research at Merck to Board of Directors
Release Date: 07/06/2017 1:55pm
Pharmaceutical research company Pharmaxis today announced it has appointed Dr Kathleen Metters to the Board of Directors. Dr Metters has more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases.
Dr Metters spent 9 years as a senior executive with Merck & Co. (Merck Sharp & Dohme (MSD) outside the United States and Canada) which included a 4 year period as senior vice president and head of Worldwide Basic Research. That was followed by an appointment to design and establish External Discovery and Preclinical Sciences, created to expand Merck’s scientific network to the greater research community in academia, biotechnology, and government; building partnerships in life sciences, medicine, engineering, and information technology.
After leaving Merck in 2011 Dr Metters was appointed President and Chief Executive Officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer. Under her leadership, Lycera developed a robust pipeline of proprietary and partnered immune modulator programs which formed the basis, in June 2015, of an exclusive global collaboration with Celgene Corporation.
Dr Metters will serve as a Non Executive Director on the Pharmaxis Board – joining current members Malcolm McComas, Simon Buckingham, Will Delaat and Gary Phillips.
Categories: News and Media